News

Clinical Trials Arena1h
PulseSight doses first subject in Phase I trial of dry AMD/GA therapy
PulseSight Therapeutics has dosed the first subject in the Phase I trial of its first-in-class non-viral vectorised therapy, PST-611.
Clinical Trials Arena23h
Eleva commences Phase I clinical trial for C3G treatment
Eleva has initiated dosing in its Phase I trial of its recombinant human complement Factor H (CPV-104) programme, for C3-glomerulopathy (C3G).
Clinical Trials Arena23h
PYC Therapeutics to begin Part B in SAD trial for polycystic kidney disease
PYC Therapeutics is set to begin Part B in its SAD study of the drug candidate, PYC-003, for polycystic kidney disease (PKD) patients.